Seekyo Therapeutics logo
VerifiedBiotechnology Research· Founded 2018

Seekyo Therapeutics

The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal…) • Low Cost of Goods

7-day free trial · no credit card

Verified contacts

3

available on Kipplo

LinkedIn employees

9

1 to 10 range

Open roles

no listings

Distinct roles

2

indexed titles

Tech stack

1

tools in use

Monthly traffic

organic / mo

Sign up free to see all 3 verified contacts at Seekyo Therapeutics

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Decision-makers and verified team members

3 contacts with verified email or phone · masked until revealed.

Sign up free →

No verified contacts on record for this company yet.

Top roles at Seekyo Therapeutics

2 distinct titles indexed · top 2 shown.

  • 1()
  • 1strategic board member

Sign up to unlock all 3 contacts at Seekyo Therapeutics

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Sign up to reveal 3 verified contacts at Seekyo Therapeutics

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.

Seekyo Therapeutics | Kipplo Discover